ArticleMediators of inflammation2006
Interleukin-10 in the pathophysiology of inflammatory bowel disease: increased serum concentrations during the recovery phase.
Article in Mediators of inflammation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 63 citations in OpenAlex.
- Inflammatory and Immune Cytoprofiles of Active Ulcerative Colitis from Crohn's Disease-Insights from Multivariable Modeling.International journal of molecular sciences · 2026Article
- Plasma FABP2, IL-10, and LPS in Microscopic Colitis: An Exploratory Study of Their Biomarker Potential.Medicina (Kaunas, Lithuania) · 2026Article
- Serum Interleukin-10 as a Potential Biomarker for Deep Remission and Histologic Activity in Ulcerative Colitis.Biomedicines · 2026Article
- Interleukin Signatures as Prognostic Biomarkers in Ulcerative Colitis: From Immune Pathways to Clinical Prediction.Current issues in molecular biology · 2026Review
- Cystic fibrosis and inflammatory bowel disease: parallels in gut physiology and microbiota.Journal of bacteriology · 2025Review
- Prediction of deep remission through serum TNF-α level at 1 year of treatment in pediatric Crohn's disease.Scientific reports · 2025Article
- Pro-inflammatory and anti-inflammatory cytokines as candidate markers in the diagnosis and assessment of Crohn's disease activity.Archives of medical science : AMS · 2025Article
- An Engineered Probiotic Produces a Type III Interferon IFNL1 and Reduces Inflammations inACS biomaterials science & engineering · 2023Article
- Toxicity and Anti-Inflammatory Activity of Phenolic-Rich Extract fromPlants (Basel, Switzerland) · 2023Article
- Evaluation of periodontal status and cytokine levels in saliva and gingival crevicular fluid of patients with inflammatory bowel diseases.Journal of periodontology · 2022Article
- Mucosal Interleukin-10 depletion in steroid-refractory Crohn's disease patients.Immunity, inflammation and disease · 2022Article
- Inflammatory bowel disease biomarkers.Medicinal research reviews · 2022Review
- Article
- Anti-Inflammatory Activity of Oat Beta-Glucans in a Crohn's Disease Model: Time- and Molar Mass-Dependent Effects.International journal of molecular sciences · 2021Article
- Extracts and Marine Algae Polysaccharides in Therapy and Prevention of Inflammatory Diseases of the Intestine.Marine drugs · 2020Review
- Correlative Monitoring of Immune Activation and Tissue Damage in Malignant Melanoma-An Algorithm for Identification of Tolerance Breakage During Immune Checkpoint Inhibitor Therapy of Cancer.International journal of molecular sciences · 2020Article
- Article
- Homoectoine Protects Against Colitis by Preventing a Claudin Switch in Epithelial Tight Junctions.Digestive diseases and sciences · 2019Article
- Low Serum Interleukin-10 Is an Independent Predictive Factor for the Risk of Second Event in Clinically Isolated Syndromes.Frontiers in neurology · 2019Article
- Immunological pathogenesis of inflammatory bowel disease.Intestinal research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using a specific enzyme-linked immunosorbent assay, IL-10 concentrations were measured in serum from 62 patients with ulcerative colitis (UC), 43 with Crohn's disease (CD), 25 with other colitides, and 44 normal control subjects. Serum IL-10 concentrations were increased in patients with active UC but not in those with active CD when compared with normal control subjects. A time course study showed that in patients with UC and CD, serum concentrations of IL-6 and C-reactive protein increased during the acute phase and returned to normal as patients go into remission. Notably, serum IL-10 concentrations increased during the phase of disease resolution and declined thereafter regardless of the treatment modality. Gel filtration analysis indicated that IL-10 circulated predominantly as a dimer. In conclusion, this study shows that serum IL-10 is increased during disease recovery in patients with inflammatory bowel disease, and may be a helpful marker in monitoring disease status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.